JP2019517582A5 - - Google Patents

Download PDF

Info

Publication number
JP2019517582A5
JP2019517582A5 JP2019515785A JP2019515785A JP2019517582A5 JP 2019517582 A5 JP2019517582 A5 JP 2019517582A5 JP 2019515785 A JP2019515785 A JP 2019515785A JP 2019515785 A JP2019515785 A JP 2019515785A JP 2019517582 A5 JP2019517582 A5 JP 2019517582A5
Authority
JP
Japan
Prior art keywords
compound
disease
colitis
ibd
positively charged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019515785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517582A (ja
JP6906047B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/035752 external-priority patent/WO2017210604A1/en
Publication of JP2019517582A publication Critical patent/JP2019517582A/ja
Publication of JP2019517582A5 publication Critical patent/JP2019517582A5/ja
Priority to JP2021106306A priority Critical patent/JP7130818B2/ja
Application granted granted Critical
Publication of JP6906047B2 publication Critical patent/JP6906047B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019515785A 2016-06-03 2017-06-02 特異的炎症収束性メディエーターの塩に関連する組成物及び方法 Active JP6906047B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021106306A JP7130818B2 (ja) 2016-06-03 2021-06-28 特異的炎症収束性メディエーターの塩に関連する組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345043P 2016-06-03 2016-06-03
US62/345,043 2016-06-03
PCT/US2017/035752 WO2017210604A1 (en) 2016-06-03 2017-06-02 Compositions and methods relating to salts of specialized pro-resolving mediators of inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021106306A Division JP7130818B2 (ja) 2016-06-03 2021-06-28 特異的炎症収束性メディエーターの塩に関連する組成物及び方法

Publications (3)

Publication Number Publication Date
JP2019517582A JP2019517582A (ja) 2019-06-24
JP2019517582A5 true JP2019517582A5 (enExample) 2020-07-16
JP6906047B2 JP6906047B2 (ja) 2021-07-21

Family

ID=59325604

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019515785A Active JP6906047B2 (ja) 2016-06-03 2017-06-02 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
JP2020529300A Active JP7368354B2 (ja) 2016-06-03 2018-11-28 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
JP2021106306A Active JP7130818B2 (ja) 2016-06-03 2021-06-28 特異的炎症収束性メディエーターの塩に関連する組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020529300A Active JP7368354B2 (ja) 2016-06-03 2018-11-28 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
JP2021106306A Active JP7130818B2 (ja) 2016-06-03 2021-06-28 特異的炎症収束性メディエーターの塩に関連する組成物及び方法

Country Status (10)

Country Link
US (5) US10130719B2 (enExample)
EP (3) EP3454907B1 (enExample)
JP (3) JP6906047B2 (enExample)
KR (1) KR102437682B1 (enExample)
CN (2) CN109562186B (enExample)
AU (1) AU2018374863B2 (enExample)
CA (2) CA3026264A1 (enExample)
DK (1) DK3454907T3 (enExample)
ES (1) ES2827796T3 (enExample)
WO (2) WO2017210604A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026264A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
ES2986149T3 (es) 2018-10-09 2024-11-08 Univ Rochester Tratamiento de trastornos vulvovaginales
US11400057B2 (en) 2018-10-19 2022-08-02 University Of Rochester Treatment of vulvar pain
GB201913383D0 (en) * 2019-09-17 2019-10-30 Univ London Queen Mary Methods for predicting patient response to DMARDs
US20210369768A1 (en) * 2020-06-01 2021-12-02 Balchem Corporation Metal di-amino acid chelates or metal tri-amino acid chelates
WO2023076329A1 (en) * 2021-10-26 2023-05-04 Thetis Pharmaceuticals Llc Compositions and methods for cancer therapy
WO2023168245A2 (en) 2022-03-03 2023-09-07 Thetis Pharmaceuticals Llc Cyclodextrin complexes of specialized proresolving mediators

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599152A (en) 1985-05-24 1986-07-08 Albion Laboratories Pure amino acid chelates
US4863898A (en) 1986-02-06 1989-09-05 Albion International, Inc. Amino acid chelated compositions for delivery to specific biological tissue sites
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US5061815A (en) 1988-07-06 1991-10-29 Zinpro Corporation Metal lysine complexes and method for producing metal lysine complexes
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
EP0459148B1 (en) 1990-05-29 1996-01-03 Ocular Research Of Boston Inc. Dry eye treatment composition
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6887901B1 (en) 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
IT1264987B1 (it) 1993-12-14 1996-10-17 Prospa Bv Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
FR2774591B1 (fr) 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
DE69918105T2 (de) 1998-04-29 2005-07-07 Sumitomo Pharmaceuticals Co., Ltd. Orale zubereitung enthaltend einen biguanid und eine organische säure
JP4526622B2 (ja) 1998-10-23 2010-08-18 北興化学工業株式会社 農園芸用種子消毒剤および種子の消毒方法
JP2000212145A (ja) 1999-01-22 2000-08-02 Hokko Chem Ind Co Ltd Nε―アシル―4―オキサリジンおよびその製造用中間体
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
CA2400804C (en) 2000-02-04 2009-09-01 Takeda Chemical Industries, Ltd. Stable emulsion compositions of cycloalkene derivatives
EP1762557B1 (en) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US6491950B1 (en) 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
US6667064B2 (en) 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
US6689385B2 (en) 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
DE10102050A1 (de) 2001-01-17 2002-07-18 Basf Ag Zubereitung zur Verbesserung der Nahrungsverwertung
EP1406698B1 (en) 2001-03-02 2008-10-29 The Brigham and Women's Hospital Lipoxin analogs as novel inhibitors of angiogenesis
JP4220247B2 (ja) 2001-03-29 2009-02-04 ビーエーエスエフ ソシエタス・ヨーロピア 共役不飽和グリセリド混合物及びその製造方法
AU2002335689B2 (en) 2001-08-31 2008-08-07 Rutgers, The State University Of New Jersey Methods for treating disorders using plant extracts
WO2003039533A1 (en) 2001-11-06 2003-05-15 The Brigham And Women's Hospital, Inc. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
WO2003068209A1 (en) 2002-02-14 2003-08-21 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
AU2003266014B2 (en) 2002-05-06 2009-05-14 Alnylam Pharmaceuticals, Inc. Methods for delivery of nucleic acids
EP1537069B1 (en) 2002-06-17 2008-01-02 Resolvyx Pharmaceuticals ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
JP4694207B2 (ja) 2002-07-05 2011-06-08 コルジウム ファーマシューティカル, インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
CA2494281A1 (en) 2002-08-02 2004-02-12 Penwest Pharmaceuticals Company Sustained release formulations of metformin
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
EP2384750A1 (en) 2002-09-27 2011-11-09 Martek Biosciences Corporation Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
US7547454B2 (en) 2002-11-07 2009-06-16 Shyam K Gupta Hydroxy acid complexes for antiaging and skin renovation
JP2004175790A (ja) 2002-11-12 2004-06-24 Arita Junichi α−グルコシダーゼ阻害作用を有する亜鉛含有物
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
MXPA05009933A (es) 2003-03-18 2005-11-04 Novartis Ag Composiciones que comprenden acidos grasos y aminoacidos.
EP1624858B1 (en) 2003-04-09 2018-06-06 Rutgers, the State University of New Jersey Novel encochleation methods
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20080045559A1 (en) 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
WO2005042539A1 (en) 2003-10-29 2005-05-12 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
WO2005041925A2 (en) 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption
WO2005070429A1 (en) 2004-01-22 2005-08-04 Neurosearch A/S Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
EP1591114A1 (en) 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
WO2005118612A1 (en) 2004-06-04 2005-12-15 Sonus Pharmaceuticals, Inc. Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs
TWI236573B (en) 2004-07-09 2005-07-21 Asia Optical Co Inc Camera lens with adjustment mechanism
CN101094683A (zh) 2004-10-29 2007-12-26 J·坎贝尔-托夫特 从催吐萝芙木和酸橙中分离的抗糖尿病提取物及其使用方法
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
EP1888728A4 (en) 2005-05-04 2010-07-14 Pronova Biopharma Norge As Fatty acid analogues, D.H. DHA DERIVATIVES FOR USE AS A MEDICAMENT
AU2006264407B2 (en) 2005-07-04 2012-08-30 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
US8273792B2 (en) * 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
US7666898B2 (en) 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
US20100121048A1 (en) 2006-02-16 2010-05-13 Takanobu Kuroita Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension
US20090047340A1 (en) 2006-03-29 2009-02-19 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis
WO2007149313A1 (en) 2006-06-16 2007-12-27 Indigene Pharmaceuticals Inc. Metformin r-(+) lipoate as an antidiabetic agent for control of diabetic hyperglycemia and diabetic complications
US20120189569A1 (en) 2006-08-06 2012-07-26 Bioderm Research Hydroxy Acid Complexes for Skin Renovation and Clarity
TW200816991A (en) * 2006-08-23 2008-04-16 Bayer Schering Pharma Ag Treatment and prevention of intestinal fibrosis
JP5552313B2 (ja) 2006-11-01 2014-07-16 プロノヴァ・バイオファーマ・ノルゲ・アーエス 脂質化合物
WO2008058274A2 (en) 2006-11-09 2008-05-15 Children's Medical Center Corporation Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization
US7906678B2 (en) * 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs
CN101652131A (zh) 2007-01-29 2010-02-17 韩兀制药株式会社 N,n-二甲基亚氨基二碳亚氨酸二酰胺乙酸盐、其制备方法和包含其的药物组合物
WO2008139941A1 (en) 2007-04-27 2008-11-20 Takeda Pharmaceutical Company Limited Substituted imidazole compound and use thereof
US20090227560A1 (en) 2007-04-27 2009-09-10 Takanobu Kuroita Substituted imidazole compound and use thereof
US20090054513A1 (en) 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
EP2203418B1 (en) 2007-09-21 2017-10-25 HanAll Biopharma Co., Ltd. N,n-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same
JP5441705B2 (ja) 2007-10-15 2014-03-12 武田薬品工業株式会社 アミド化合物およびその用途
EP2300031B1 (en) 2008-05-05 2017-09-20 Oramed Ltd. Methods and compositions for oral administration of exenatide
JO3465B1 (ar) 2008-06-19 2020-07-05 Takeda Pharmaceuticals Co مركب متغاير الحلقه واستخدامه
CN102159539B (zh) 2008-06-26 2014-04-16 矽烷实验室股份公司 用于血糖控制的新型二甲双胍甘氨酸盐
FR2934519B1 (fr) 2008-08-01 2013-06-28 Oreal Procede de fabrication d'un premier recipient de produit cosmetique, moule, col et recipient associes
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN108096209A (zh) 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
WO2011034887A2 (en) 2009-09-15 2011-03-24 The Brigham And Women's Hospital, Inc. A method for treating neuropathic pain
PL217815B1 (pl) 2009-12-14 2014-08-29 Olimp Lab Spółka Z Ograniczoną Odpowiedzialnością Napój izotoniczny z chelatami
US8178707B2 (en) 2010-03-25 2012-05-15 Jost Chemical Company Co-precipitated salts of fatty acids
US20110052678A1 (en) 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
WO2012141316A1 (ja) 2011-04-13 2012-10-18 味の素株式会社 栄養組成物
CN107050457A (zh) 2012-01-06 2017-08-18 翁特拉制药公司 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物
US9804156B2 (en) 2012-03-06 2017-10-31 Life Technologies Corporation Biomarkers for systemic lupus erythematosus
JP6370775B2 (ja) 2012-05-10 2018-08-08 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
WO2013192109A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
US20140011814A1 (en) 2012-07-06 2014-01-09 Thetis Pharmaceuticals Llc Diamine and meglumine salt forms of fatty acids
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
CN104684889A (zh) 2012-07-10 2015-06-03 西蒂斯制药有限责任公司 二甲双胍的三盐形式
WO2014011895A2 (en) 2012-07-11 2014-01-16 Thetis Pharmaceuticals Llc High solubility acid salts, intravenous dosage forms, nutrition supplementation and methods of use thereof
AU2012227298B2 (en) 2012-09-25 2015-02-12 Jost Chemical Co. Co-precipitated salts of fatty acids
TW201416726A (zh) 2012-10-26 2014-05-01 Dongguan Masstop Liquid Crystal Display Co Ltd 具有觸控功能之彩色濾光片基板
US9394318B2 (en) 2012-11-30 2016-07-19 Cypress Pharmaceuticals, Inc. Crystal polymorph of magnesium glycinate dihydrate and process for its preparation
CN103340300A (zh) 2013-06-06 2013-10-09 李才平 一种绿色生态鲫鱼饲料的配制方法
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
KR20170023061A (ko) * 2014-06-18 2017-03-02 테티스 파마수티컬스 엘엘씨 활성제의 미네랄 아미노산 복합체
US9242008B2 (en) * 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
CN104430341B (zh) 2014-12-10 2016-09-28 青岛大学 天然有机酸根褐藻氨酸螯合物在农用制剂中的应用
US10653703B2 (en) 2015-09-03 2020-05-19 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same
GB201522132D0 (en) 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Vaccine
CA3026264A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators

Similar Documents

Publication Publication Date Title
JP2013032389A5 (enExample)
JP2021530565A5 (enExample)
JP2008509166A5 (enExample)
JP2018509143A5 (enExample)
JP2016540742A5 (enExample)
JP2013523975A5 (enExample)
JP2021513534A5 (enExample)
JP2015500795A5 (enExample)
JP2024516371A5 (enExample)
JP2016532667A5 (enExample)
JP2010506979A5 (enExample)
JP2012504133A5 (enExample)
JP2011513410A5 (enExample)
JP2017536395A5 (enExample)
JP2016534148A5 (enExample)
JP2013510885A5 (enExample)
JP2020097577A5 (enExample)
JP2010527913A5 (enExample)
JP2020507589A5 (enExample)
JP2013540864A5 (enExample)
JP2019516739A5 (enExample)
JP2015512946A5 (enExample)
JP2019523752A5 (enExample)
JP2018521056A5 (enExample)
JP2013515037A5 (enExample)